Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Laurent SA, Strauli NB, Eggers EL, Wu H, Michel B, Demuth S, Palanichamy A, Wilson MR, Sirota M, Hernandez RD, Cree BAC, Herman AE, von Büdingen HC. Laurent SA, et al. Among authors: palanichamy a. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 24;10(4):e200118. doi: 10.1212/NXI.0000000000200118. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37094998 Free PMC article. Clinical Trial.
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
Schett G, Loza MJ, Palanichamy A, FitzGerald O, Ritchlin C, Bay-Jensen AC, Nielsen SH, Gao S, Hsia EC, Kollmeier AP, Xu XL, Baribaud F, Sweet K. Schett G, et al. Among authors: palanichamy a. Rheumatol Ther. 2022 Aug;9(4):1247-1248. doi: 10.1007/s40744-022-00470-9. Rheumatol Ther. 2022. PMID: 35779224 Free PMC article. No abstract available.
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
Schett G, Loza MJ, Palanichamy A, FitzGerald O, Ritchlin C, Bay-Jensen AC, Nielsen SH, Gao S, Hsia EC, Kollmeier AP, Xu XL, Baribaud F, Sweet K. Schett G, et al. Among authors: palanichamy a. Rheumatol Ther. 2022 Aug;9(4):1017-1030. doi: 10.1007/s40744-022-00444-x. Epub 2022 Mar 30. Rheumatol Ther. 2022. PMID: 35352313 Free PMC article.
Intrathecal B-cell activation in LGI1 antibody encephalitis.
Lehmann-Horn K, Irani SR, Wang S, Palanichamy A, Jahn S, Greenfield AL, Dandekar R, Lepennetier G, Michael S, Gelfand JM, Geschwind MD, Wilson MR, Zamvil SS, von Büdingen HC. Lehmann-Horn K, et al. Among authors: palanichamy a. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 6;7(2):e669. doi: 10.1212/NXI.0000000000000669. Print 2020 Mar. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32029531 Free PMC article.
Failure of B Cell Tolerance in CVID.
Richardson CT, Slack MA, Dhillon G, Marcus CZ, Barnard J, Palanichamy A, Sanz I, Looney RJ, Anolik JH. Richardson CT, et al. Among authors: palanichamy a. Front Immunol. 2019 Dec 10;10:2881. doi: 10.3389/fimmu.2019.02881. eCollection 2019. Front Immunol. 2019. PMID: 31921145 Free PMC article. Clinical Trial.
Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.
Adlowitz DG, Barnard J, Biear JN, Cistrone C, Owen T, Wang W, Palanichamy A, Ezealah E, Campbell D, Wei C, Looney RJ, Sanz I, Anolik JH. Adlowitz DG, et al. Among authors: palanichamy a. PLoS One. 2015 Jun 5;10(6):e0128269. doi: 10.1371/journal.pone.0128269. eCollection 2015. PLoS One. 2015. PMID: 26047509 Free PMC article.
19 results